JP6774340B2 - 後眼部障害を処置するための方法およびデバイス - Google Patents

後眼部障害を処置するための方法およびデバイス Download PDF

Info

Publication number
JP6774340B2
JP6774340B2 JP2016573927A JP2016573927A JP6774340B2 JP 6774340 B2 JP6774340 B2 JP 6774340B2 JP 2016573927 A JP2016573927 A JP 2016573927A JP 2016573927 A JP2016573927 A JP 2016573927A JP 6774340 B2 JP6774340 B2 JP 6774340B2
Authority
JP
Japan
Prior art keywords
drug
eye
administered
months
uveitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016573927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524677A (ja
JP2017524677A5 (enExample
Inventor
グレン ノローニャ，
グレン ノローニャ，
クリストファー ジョン ブルックス，
クリストファー ジョン ブルックス，
ラファエル ビクター アンディノ，
ラファエル ビクター アンディノ，
サミルクマール パテル，
サミルクマール パテル，
ダニエル ホワイト，
ダニエル ホワイト，
Original Assignee
クリアサイド バイオメディカル，インコーポレイテッド
クリアサイド バイオメディカル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリアサイド バイオメディカル，インコーポレイテッド, クリアサイド バイオメディカル，インコーポレイテッド filed Critical クリアサイド バイオメディカル，インコーポレイテッド
Publication of JP2017524677A publication Critical patent/JP2017524677A/ja
Publication of JP2017524677A5 publication Critical patent/JP2017524677A5/ja
Application granted granted Critical
Publication of JP6774340B2 publication Critical patent/JP6774340B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
JP2016573927A 2014-06-17 2015-06-17 後眼部障害を処置するための方法およびデバイス Active JP6774340B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462013209P 2014-06-17 2014-06-17
US62/013,209 2014-06-17
US201462018148P 2014-06-27 2014-06-27
US62/018,148 2014-06-27
US201462063792P 2014-10-14 2014-10-14
US62/063,792 2014-10-14
US201562155367P 2015-04-30 2015-04-30
US62/155,367 2015-04-30
US201562156802P 2015-05-04 2015-05-04
US62/156,802 2015-05-04
PCT/US2015/036299 WO2015195842A1 (en) 2014-06-17 2015-06-17 Methods and devices for treating posterior ocular disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019172752A Division JP2020063236A (ja) 2014-06-17 2019-09-24 後眼部障害を処置するための方法およびデバイス

Publications (3)

Publication Number Publication Date
JP2017524677A JP2017524677A (ja) 2017-08-31
JP2017524677A5 JP2017524677A5 (enExample) 2018-07-26
JP6774340B2 true JP6774340B2 (ja) 2020-10-21

Family

ID=54936084

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016573927A Active JP6774340B2 (ja) 2014-06-17 2015-06-17 後眼部障害を処置するための方法およびデバイス
JP2019172752A Pending JP2020063236A (ja) 2014-06-17 2019-09-24 後眼部障害を処置するための方法およびデバイス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019172752A Pending JP2020063236A (ja) 2014-06-17 2019-09-24 後眼部障害を処置するための方法およびデバイス

Country Status (12)

Country Link
US (1) US20180042765A1 (enExample)
EP (1) EP3157463A4 (enExample)
JP (2) JP6774340B2 (enExample)
KR (1) KR102511477B1 (enExample)
CN (1) CN107072765A (enExample)
AU (1) AU2015277133A1 (enExample)
BR (1) BR112016029864A2 (enExample)
CA (1) CA2952822A1 (enExample)
IL (1) IL249602A0 (enExample)
MX (1) MX2016016836A (enExample)
RU (1) RU2017101236A (enExample)
WO (1) WO2015195842A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
BR112013009205A2 (pt) 2010-10-15 2016-07-26 Iscience Interventional Corp dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho.
CA3240136A1 (en) 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
SG10201702674PA (en) 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
EP3003454B1 (en) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Apparatus for drug delivery using multiple reservoirs
CN106687078B (zh) 2014-02-12 2019-10-25 轨道生物医学有限公司 用于治疗剂的脉络膜上施用的方法和设备
US9949874B2 (en) 2014-06-06 2018-04-24 Janssen Biotech, Inc. Therapeutic agent delivery device with convergent lumen
US9925088B2 (en) 2014-06-06 2018-03-27 Janssen Biotech, Inc. Sub-retinal tangential needle catheter guide and introducer
RU2710491C2 (ru) 2014-06-20 2019-12-26 Клиасайд Байомедикал, Инк. Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10219936B2 (en) 2014-09-11 2019-03-05 Orbit Biomedical Limited Therapeutic agent delivery device with advanceable cannula and needle
US10258502B2 (en) 2014-09-18 2019-04-16 Orbit Biomedical Limited Therapeutic agent delivery device
TWI705827B (zh) * 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3400014A1 (en) * 2016-01-08 2018-11-14 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
EP3448495A4 (en) 2016-01-19 2020-02-12 Dr. Py Institute, LLC DEVICES AND METHODS FOR FORMULATION PROCESSING
EP3413851B1 (en) 2016-02-10 2023-09-27 Clearside Biomedical, Inc. Packaging
US10478553B2 (en) 2016-03-09 2019-11-19 Orbit Biomedical Limited Apparatus for subretinal administration of therapeutic agent via a curved needle
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
US10806629B2 (en) 2016-06-17 2020-10-20 Gyroscope Therapeutics Limited Injection device for subretinal delivery of therapeutic agent
US11000410B2 (en) 2016-06-17 2021-05-11 Gyroscope Therapeutics Limited Guide apparatus for tangential entry into suprachoroidal space
US10646374B2 (en) 2016-06-17 2020-05-12 Orbit Biomedical Limited Apparatus and method to form entry bleb for subretinal delivery of therapeutic agent
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
US11273072B2 (en) 2017-01-13 2022-03-15 Gyroscope Therapeutics Limited Suprachoroidal injection device
EP3592377A4 (en) 2017-03-09 2021-02-17 Diamedica Inc. TISSUE KALLICREIN DOSAGE FORMS 1
US11076984B2 (en) 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
JP7332602B2 (ja) * 2017-12-28 2023-08-23 センジュ ユーエスエー、インコーポレイテッド 経皮薬物送達システムおよびその使用方法
WO2019161272A1 (en) 2018-02-15 2019-08-22 North Carolina State University Synthesis of micron and nanoscale carbon spheres and structures using hydrothemal carbonization
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
AU2019230001A1 (en) * 2018-03-05 2020-09-24 Massachusetts Eye And Ear Infirmary Amelioration of autoimmune uveitis through blockade of CSF1R
WO2019217678A1 (en) * 2018-05-09 2019-11-14 North Carolina State University Applicator for corneal therapeutics
US11039954B2 (en) * 2019-03-21 2021-06-22 Microoptx Inc. Implantable ocular drug delivery devices and methods
CN110009626A (zh) * 2019-04-11 2019-07-12 北京百度网讯科技有限公司 用于生成图像的方法和装置
CA3136814A1 (en) 2019-04-16 2020-10-22 Clearside Biomedical, Inc. Injectable triamcinolone formulations
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4106755A4 (en) * 2020-02-19 2024-03-27 Clearside Biomedical, Inc. COMPOSITIONS CONTAINING AXITINIB AND METHODS FOR TREATING OCULAR DISEASES
EP4181985A1 (en) * 2020-07-17 2023-05-24 SHL Medical AG Micro dosing device and method of assembly of the micro dosing device
CA3200332A1 (en) * 2020-12-02 2022-06-09 Telios Pharma, Inc. Methods and compositions for treating an ophthalmic condition
JP2024500871A (ja) * 2020-12-17 2024-01-10 モビアス セラピューティクス， エルエルシー 注射装置および使用方法
CN113101502B (zh) * 2021-03-01 2023-01-17 李特 一种耳鼻喉科用治疗装置
CN113198003A (zh) * 2021-06-22 2021-08-03 万永年 一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法
US20250177417A1 (en) * 2022-01-06 2025-06-05 Clearside Biomedical, Inc. Compositions and methods for treating macular edema associated with uveitis
TWI866393B (zh) * 2022-08-16 2024-12-11 美商奧伊斯特普安生物製藥公司 經組態用於液體產品之無菌轉移的施配器
WO2024064848A2 (en) * 2022-09-23 2024-03-28 Inoculus Ventures, Inc. Dry eye treatment
US12370201B2 (en) * 2023-07-10 2025-07-29 Eden Ophthalmic Pte Ltd. Liposomal formulations of corticosteroids and uses thereof
WO2025179248A1 (en) * 2024-02-23 2025-08-28 Oculogenex Inc. Microneedle device for intraocular injections and methods of using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2951938B1 (ja) * 1998-03-19 1999-09-20 日本ケミカルリサーチ株式会社 薬剤溶解機構を内蔵した注射器
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005072701A1 (en) * 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) * 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2008070479A2 (en) * 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
US8083759B2 (en) * 2007-11-02 2011-12-27 Refocus Ocular, Inc. Apparatuses and methods for forming incisions in ocular tissue
US8221353B2 (en) * 2008-10-21 2012-07-17 KMG Pharma, Inc Intravitreal injection device and system
HUE054113T2 (hu) * 2010-08-05 2021-08-30 Forsight Vision4 Inc Injekciós készülék gyógyszerbejuttatáshoz
US20120101475A1 (en) * 2010-10-21 2012-04-26 Meridian Medical Technologies, Inc. High Efficiency Auto-Injector
EP2578260A1 (en) * 2011-10-07 2013-04-10 Sanofi-Aventis Deutschland GmbH Apparatus for intraocular injection
CA3240136A1 (en) * 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
CA2933900A1 (en) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents

Also Published As

Publication number Publication date
RU2017101236A (ru) 2018-07-17
WO2015195842A1 (en) 2015-12-23
AU2015277133A1 (en) 2017-02-02
JP2020063236A (ja) 2020-04-23
US20180042765A1 (en) 2018-02-15
CN107072765A (zh) 2017-08-18
JP2017524677A (ja) 2017-08-31
CA2952822A1 (en) 2015-12-23
KR20170039128A (ko) 2017-04-10
KR102511477B1 (ko) 2023-03-16
BR112016029864A2 (pt) 2017-08-22
EP3157463A4 (en) 2018-02-21
IL249602A0 (en) 2017-02-28
EP3157463A1 (en) 2017-04-26
RU2017101236A3 (enExample) 2019-05-16
MX2016016836A (es) 2017-07-27

Similar Documents

Publication Publication Date Title
JP6774340B2 (ja) 後眼部障害を処置するための方法およびデバイス
JP7082599B2 (ja) ヒト被験体における眼部障害の処置のための方法およびデバイス
JP2019501200A (ja) 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス
HK40041836A (en) Methods for the treatment of ocular disease in human subjects
HK40041836B (en) Methods for the treatment of ocular disease in human subjects
HK1235263A1 (en) Methods and devices for treating posterior ocular disorders
HK1213192B (en) Methods for the treatment of ocular disease in human subjects

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201002

R150 Certificate of patent or registration of utility model

Ref document number: 6774340

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250